topiramate augmentation in refractory obsessive- compulsive disorder: a randomized, double-blind, placebo-controlled trial
نویسندگان
چکیده
background: this study aimed to assess the effectiveness of topiramate, a glutamate-modulating agent, in patients with treatment-resistant obsessive-compulsive disorder (ocd) as an adjunct to serotonin reuptake inhibitors (sris). materials and methods: thirty-eight patients with refractory ocd, were randomly assigned to receive topiramate or placebo. this study was designed as a 12-week, double-blind, placebo-controlled trial. primary outcome measures were the change in yale-brown obsessive compulsive scale (y-bocs) score and the rate of treatment response in each group at the study end point. treatment response was considered as 25% or more reduction in y-bocs score. results: 13 patients in the topiramate group and 14 ones in the placebo group completed the trial. topiramate-assigned patients showed significantly improved mean y-bocs score over time (p<0.001). although differences between two groups was significant in the y-bocs score at the first two months (p=0.01), this was not significant at the end of study (p=0.10). changes of clinical global impression (cgi)-severity of illness scale score and cgi-improvement scale score were not significantly different between two groups (p>0.05).treatment response was almost significantly different in the topiramate group comparing placebo group (p=0.054). mean topiramate dosage was 137.5 mg/day (range, 100-200). conclusion: this study didn’t show effectiveness of topiramate as an agent to augment sris in treatment-resistant ocd patients.
منابع مشابه
Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial
BACKGROUND This study aimed to assess the efficacy of topiramate, a glutamate-modulating agent, in patients with treatment-resistant obsessive-compulsive disorder (OCD) as an adjunct to serotonin reuptake inhibitors (SRIs). MATERIALS AND METHODS Thirty-eight patients with refractory OCD, were randomly assigned to receive topiramate or placebo. This study was designed as a 12 weeks, double-bli...
متن کاملefficacy of n-acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial
objective: glutamate is considered a target for treating obsessive-compulsive disorder (ocd). the efficacy and safety of the nutritional supplement of n-acetylcysteine (nac) as an adjuvant to serotonin reuptake inhibitor (ssri) for treating children and adolescents with ocd has never been examined. methods: this was a 10-week randomized double-blind placebo-controlled clinical trial with 34 ocd...
متن کاملEfficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial
Objective: Glutamate is considered a target for treating obsessive-compulsive disorder (OCD). The efficacy and safety of the nutritional supplement of N-Acetylcysteine (NAC) as an adjuvant to serotonin reuptake inhibitor (SSRI) for treating children and adolescents with OCD has never been examined. Method: This was a 10-week randomized double-blind placebo-controlled clinical trial with 34 OCD ...
متن کامل lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial
objective: serotonin reuptake inhibitors are frequently used in first-line treatments for patients with obsessive-compulsive disorder. nevertheless, many of these patients do not respond well to initial therapy. the hypothesis of glutamatergic dysfunction in specific brain regions has been proposed in the pathophysiology of obsessive-compulsive disorder. this study was designed to evaluate ...
متن کاملQuetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
BACKGROUND Although serotonin reuptake inhibitors are effective in the treatment of OCD, many patients fail to respond to these agents. Growing evidence from open-label and placebo-controlled trials suggests a role for augmentation of SRIs with atypical antipsychotics in OCD. Quetiapine is generally well tolerated and previous open-label data has produced mixed results in OCD and additional con...
متن کاملLamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial
OBJECTIVE Serotonin reuptake inhibitors are frequently used in first-line treatments for patients with obsessive-compulsive disorder. Nevertheless, many of these patients do not respond well to initial therapy. The hypothesis of glutamatergic dysfunction in specific brain regions has been proposed in the pathophysiology of obsessive-compulsive disorder. This study was designed to evaluate the p...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
journal of research in medical sciencesجلد ۱۹، شماره ۱۰، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023